VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb†or the "company†), a leading global eye health company dedicated to helping people see better to live better, today announced that it allocated a $2,802,125,000 tranche (the "Replacement Term Loans†) of new term B loans, the proceeds of which will be used to refinance all of its outstanding term B loans due 2031 (the "Third Amendment Term Loans†) and its outstanding term B loans due 2028 (the "First Increment ...

​Bausch + Lomb Corporation (NYSE:BLCO) is one of the Best Up and Coming Canadian Stocks to Buy. Wall Street has a cautious outlook on the stock despite an 8.59% increase in share price during the month. ​On November 13, Bausch + Lomb Corporation (NYSE:BLCO) highlighted its growth strategy at investor day. The management noted they have increased their focus on simplification and rebuilt the culture to embrace AI and technological innovation. The company unveiled that it targets 5% to 7% CAGR through 2028, ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

One fund just made a bold move on an eye-care giant—here’s why it may signal a deeper shift in the company’s long-term trajectory.Connecticut-based Silver Point Capital initiated a new position in Bausch + Lomb Corporation (BLCO 0.91%), adding nearly 2.6 millino shares for an estimated $38.7 million, per its November 14 SEC filing.What HappenedAccording to a filing with the Securities and Exchange Commission dated November 14, Silver Point Capital disclosed a new stake in Bausch + Lomb Corporation (BLCO 0.9 ...

Bausch + Lomb (NYSE:BLCO) FY 2025 Conference December 03, 2025 09:00 AM ET Company ParticipantsBrent Saunders - CEOSam Eldessouky - CFOConference Call ParticipantsNone - AnalystNoneHello, and good morning, everybody, to day two of the Citibank Global Healthcare conference here in Miami. And I am Joanne Lynch, the medical technology analyst here. And I'm thrilled that we're going to start this session with the management of Bausch + Lomb. Brent Saunders is Chairman and CEO, and Sam, oh, I'm going to call you ...

Financial Data and Key Metrics Changes - The company is focused on achieving financial excellence, particularly improving EBITDA margins to align with or exceed competitors [5][6][11] - A three-year plan was announced, targeting a revenue growth rate of 5%-7% [13][15] - The company aims for a net leverage of 3.5 times by 2028 [18] Business Line Data and Key Metrics Changes - The Vision 27 program is designed to enhance operational efficiency and gross margins across various business lines [6][11] - The contact lens segment is expected to grow faster than the market, with a new bioactive platform, Project Halo, set to launch in 2028 [21][27] - The dry eye product portfolio, including Xiidra and Miebo, is positioned as the gold standard in the market [52] Market Data and Key Metrics Changes - The contact lens market has slowed to about 4% growth, influenced by economic conditions in Asia, particularly China [28][29] - The company anticipates a recovery in the contact lens market, projecting growth to return to 5% or higher by 2026 [29] Company Strategy and Development Direction - The company is committed to organic growth, with no M&A planned in the three-year strategy [18] - Focus on innovation is critical, with a deep pipeline of products expected to drive future growth [90] - The company aims to leverage its existing infrastructure for new product launches to maintain high margins [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation into a high-performance competitor, emphasizing the importance of innovation and operational excellence [5][6] - The management highlighted the need for a disciplined approach to spending as growth resumes [9][11] - The company is optimistic about the aging population's demand for premium IOLs, viewing it as a growth driver [89] Other Important Information - The company is focusing on enhancing its R&D efficiency, aiming to allocate more resources towards product development rather than administrative costs [50] - The introduction of new products like Lumify Luxe and the expansion of the PreserVision brand are seen as significant growth opportunities [44][46] Q&A Session Summary Question: How should investors think about the liquidity of Bausch + Lomb given its ownership structure? - Management acknowledged the 88% ownership by Bausch Health and indicated that both boards are committed to addressing liquidity issues, though the timeline is uncertain [12] Question: What are the components of the 5%-7% revenue long-range plan? - Management explained that the guidance is based on current market conditions and internal capabilities, with a balanced approach to growth [13][15] Question: How does the company view tuck-in M&A opportunities? - Management stated that no M&A is needed at this time, focusing instead on organic growth and improving the balance sheet [18] Question: What is the expected timeline for the new bioactive contact lens material? - The new product is expected to launch in 2028, with ongoing clinical studies providing positive data [24][27] Question: How does the company plan to manage its R&D budget? - The company is increasing its R&D spending to about 7.5% of revenue, focusing on high-potential programs [48][50] Question: What is the outlook for the dry eye market? - Management believes they have the best portfolio for dry eye treatment, with Xiidra and Miebo positioned as leading products [52] Question: What is the growth outlook for the surgical business? - The surgical business is expected to grow steadily, driven by an aging population and consistent demand for IOLs [89]

Core Insights - Bausch + Lomb is positioning itself as a leading company in eye health, emphasizing a commitment to innovation and improvement in standards of care [1][2] - The company has undergone significant operational changes since 2023, focusing on not accepting the status quo and enhancing decision-making processes [2] - The current product pipeline is described as the strongest and most forward-looking in the company's history, grounded in scientific research and a clear purpose [3]

Summary of Bausch + Lomb Investor Day Company Overview - **Company**: Bausch + Lomb (NYSE: BLCO) - **Event**: 2025 Investor Day held on November 13, 2025 Key Industry Insights - **Market Growth**: The eye care market is durable and growing at mid-single digits, with Bausch + Lomb expecting a compound annual growth rate (CAGR) of 5%-7% through 2028 [19][22] - **Consumer Trends**: Increasing consumer interest in self-care, an aging population, and a rise in eye conditions, particularly dry eye, are driving market growth [51] Core Company Strategies - **Financial Excellence**: Emphasis on driving execution, controlling costs, and expanding margins to create sustainable value through 2028 and beyond [16][17] - **Innovation Focus**: A robust pipeline of breakthrough products is expected to deliver significant value beyond 2028, with over 60 active programs in various stages of development [18][34] Financial Targets - **Revenue Growth**: Expected above-market revenue growth with a target of 5%-7% CAGR through 2028 [19][22] - **Margin Expansion**: Targeting an adjusted EBITDA margin of 23% by 2028, reflecting a 600 basis points improvement from 2025 guidance [20][21] - **Cash Flow Generation**: Anticipating cash flow conversion to exceed 50% by 2028, with strong progress already noted in Q3 results [20][28] Product Portfolio Highlights - **Consumer Business**: Strong performance with a 5%-7% CAGR expected, driven by brands like PreserVision, Lumify, and Blink [23][51] - **Pharmaceutical Leadership**: Market leader in dry eye disease with brands Mibo and Xiidra, focusing on innovative treatments [24] - **Surgical Innovations**: Premium IOL portfolio and new product launches are driving growth in the surgical segment [24] Key Product Innovations - **PreserVision AREDS3**: A new formulation targeting all stages of age-related macular degeneration (AMD), expected to launch in 2026 [54][55] - **Lumify Lux**: A new version of the popular redness reliever incorporating hyaluronic acid for enhanced user experience [60][61] - **Blink Triple Care**: An advanced OTC dry eye drop formulation combining hyaluronic acid with nano-emulsion lipids for long-lasting hydration [64] R&D and Innovation - **R&D Transformation**: Significant restructuring to enhance capabilities, focusing on groundbreaking innovations and faster market delivery [33][34] - **Pipeline Potential**: Aiming for peak sales of $7 billion from the current pipeline, with a focus on disruptive innovations rather than incremental improvements [30][31] Market Position and Competitive Advantage - **Leadership in Consumer Eye Health**: Bausch + Lomb is the number one global consumer eye health company, outperforming peers in growth [51][52] - **Brand Trust**: Strong consumer trust in brands like PreserVision, Lumify, and Biotrue, which are highly recommended by eye care professionals [52] Conclusion - Bausch + Lomb is positioned for significant growth through innovative product development, strong financial management, and a commitment to improving eye health standards. The company is confident in its ability to deliver above-market growth and expand profitability through disciplined execution and strategic investments in R&D.

INVESTOR DAY November 13th, 2025 Disclaimers Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements regarding future prospects and performance of Bausch + Lomb Corporation ("Bausch + Lomb", the "Company", "we", "us", or "B+L"), our 2025 full year guidance, our three year financial targets (including targets for Company and segment ...

Core Message - The company is outlining a three-year plan aimed at achieving profitable growth and improving financial margins by approximately 600 basis points over the next three years [2][4]. Financial Strategy - The plan includes a focus on financial excellence, with a commitment to grow above market rates and enhance margins through various initiatives [2]. - The company aims to modernize its manufacturing footprint, which has been described as somewhat outdated, to create efficiencies in manufacturing and supply chain [5]. Business Segments - The surgical segment is expected to be the largest contributor to margin expansion, particularly through the introduction of higher premium intraocular lenses and implants [4]. - The company is also focusing on a diverse product mix across its consumer, pharmaceuticals, and surgical businesses to drive higher-margin products through its pipeline and R&D efforts [3]. Capital Allocation and M&A - The company is adopting a disciplined capital allocation approach, with a focus on small M&A and licensing, primarily for intellectual property to develop new medicines or products [6]. - There is a commitment to achieve a leverage ratio of three to three and a half times by 2028, aiming for an investment-grade credit rating [6]. Impact of Tariffs - Tariffs are impacting the company by approximately 40 basis points of margin this year, equating to about $20 million, primarily due to reciprocal tariffs affecting exports to China and Europe [7][8]. - The company is planning to shift some production from the U.S. to Europe and Asia in response to these tariffs [9][10]. Future Outlook - The company is preparing for a long-term environment of tariffs, indicating that it is planning around a new baseline for revenue impacted by tariffs [12]. - There are ongoing concerns about myopia in children due to screen time, and the company is developing a contact lens specifically designed for kids that incorporates therapeutic correction [20].